May 14, 2026 a 05:00 pm
ZTS: Analysts Ratings - Zoetis Inc.
Zoetis Inc. has a consistent track record in the animal health sector, providing a diverse range of medical and nutritional products for livestock and companion animals. With stable market performance and strong product lines, the company continues to be a reliable investment. However, shifts in analyst recommendations suggest a cautious sentiment, aligning with broader market trends in the sector.
Historical Stock Grades
Analyzing the latest data reveals a consistent pattern of ratings for Zoetis Inc. with a distinct lack of negative sentiment.
| Rating Category | Number | Score Bar |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 9 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- Throughout 2026, we observe stable numbers for "Strong Buy" and "Buy" recommendations.
- Hold recommendations experienced a notable increase, suggesting a more cautious approach by analysts.
- In comparison, no sell recommendations indicate sustained confidence in the stock's performance.
- Overall sentiment has shifted slightly more towards holding, reflecting broader market uncertainties.
Percentage Trends
- The distribution of analyst ratings shows a prominent shift from "Strong Buy" to "Hold" over the months, indicating increased conservativeness.
- Between May 2025 and May 2026, Hold ratings rose from 24% to 32%. Meanwhile, Strong Buy ratings decreased from 19% to 16%.
- This trend points to analysts' cautious optimism, factoring in market volatility and business environment risks.
- The stable number of "Buy" ratings, which fluctuates around 33%, suggests continued confidence without aggressive buying sentiment.
Latest Analyst Recommendations
The latest analyst recommendations hold a neutral to slightly overweight stance on Zoetis Inc., reflecting sustained business confidence.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-05-08 | Neutral | Neutral | UBS |
| 2026-05-08 | Overweight | Overweight | JP Morgan |
| 2026-04-28 | Neutral | Neutral | UBS |
| 2026-02-13 | Neutral | Neutral | B of A Securities |
| 2026-01-22 | Neutral | Overweight | Piper Sandler |
Analyst Recommendations with Change of Opinion
Adjustments in recommendations indicate a cautious reassessment by analysts, reflective of broader conditions and company-specific factors.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-22 | Neutral | Overweight | Piper Sandler |
| 2025-07-17 | Market Perform | Outperform | Leerink Partners |
| 2025-06-18 | Hold | Buy | Stifel |
| 2021-07-16 | Market Perform | Outperform | Raymond James |
| 2021-03-08 | Buy | Neutral | B of A Securities |
Interpretation
The current sentiment towards Zoetis Inc. evidences moderate optimism with some reservations. The steady increase in "Hold" ratings reflects a cautious stance by analysts, while consistent "Buy" ratings suggest ongoing, yet tempered confidence. The absence of "Sell" recommendations implies a baseline trust in the company's prospects, albeit with growing market uncertainty influencing a more conservative outlook. Analysts' sentiment stability appears moderate, with noted downgrades indicating adjustments to perceived risk factors.
Conclusion
Zoetis Inc. maintains a firm position in the animal health industry, supported by a reliable product pipeline. While analyst sentiment remains largely confident, the increase in "Hold" ratings signals caution amidst broader market volatilities. This suggests a balanced outlook where opportunities are tempered by potential risks in the economic landscape. Investors should consider potential shifts in market dynamics and inherent risks embedded in animal healthcare's evolving landscape when evaluating Zoetis as an investment option.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years